Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quadrivalent meningococcal conjugate vaccine (A, C, W135, Y)
- Development stage
- Preclinical
- Lead developer
- 罗益
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The quadrivalent meningococcal conjugate vaccine (A, C, W135, Y) is a multivalent vaccine candidate developed by Wuxi Royal Biological (Luoyi Biological) for the prevention of invasive meningococcal disease. The vaccine targets four primary serogroups of *Neisseria meningitidis*: A, C, W135, and Y. It utilizes a conjugate technology platform where capsular polysaccharides from each of the four serogroups are chemically linked to a carrier protein. This conjugation process is designed to stimulate a T-cell dependent immune response, which provides superior immunogenicity and longer-lasting protection compared to plain polysaccharide vaccines, especially in pediatric populations. As of the current pipeline status, the vaccine is in the preclinical stage of development.
- Other names
- 四价脑膜炎球菌结合疫苗A,C,W135,Y Meningococcal Conjugate VaccineMCV4MCV-4MCV 4
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on quadrivalent meningococcal conjugate vaccine (A, C, W135, Y).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on quadrivalent meningococcal conjugate vaccine (A, C, W135, Y).